Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.63 |
| ▸ | RGS12 | O14924 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | THPO | P40225 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314737 | 1.00 | KMT2A (0.63) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1314734 | 1.00 | KMT2A (0.63) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1314736 | 1.00 | KMT2A (0.63) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL14304074 | 0.87 | KMT2A (0.63) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1316007 | 0.81 | STAT3 (0.65) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1316011 | 0.81 | STAT3 (0.65) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1316013 | 0.81 | STAT3 (0.65) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1316009 | 0.81 | STAT3 (0.65) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL13051232 | 0.79 | KMT2A (0.77) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1316113 | 0.78 | STAT3 (0.61) | KMT2AMEN1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094343-A1 | ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-02 | — | — | US | disclosed |
| US-8779151-B2 | Orally bioavailable caffeic acid related anticancer drugs | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2514742-A2 | Orally bioavailable cafeic acid related anticancer drugs | The Board of Regents of The University of Texas System (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2506852-A2 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | Board Of Regents, The University Of Texas System (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011069141-A2 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20070232668-A1 | Orally Bioavailable Caffeic Acid Related Anticancer Drugs | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232668-A1 | Orally Bioavailable Caffeic Acid Related Anticancer Drugs | STAT3, JAK2, STAT5A | KMT2A 857/4885MEN1 4127/4885MAPT 4649/4885 |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | VHL, PRKDC, POLR1C | KMT2A 508/4885MEN1 2918/4885MAPT 4557/4885 |
| US-20150094343-A1 | ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS | STAT3, JAK2, STAT5A | KMT2A 857/4885MEN1 4127/4885MAPT 4649/4885 |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | STAT3, STAT1, STAT5B | KMT2A 2412/4885MEN1 1520/4885MAPT 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.